MEI Pharma (MEIP) and Kyowa Kirin Reports Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
MEI Pharma (MEIP) Prices 17.5M Share Offering at $2.60/sh
December 2, 2021 5:56 AM ESTMEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced today that it has priced the underwritten public offering of 17,500,000 shares of its common stock at $2.60 per share for total gross proceeds (before underwriting discount and commissions and estimated expenses) of $45,500,000. In connection with the offering, the Company granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of common stock offered in the public offering. The offering is expected to close on December 6, 2021, subject to the satisfaction of customary closing... More
MEI Pharma’s (MEIP) zandelisib Has Best-in-Class Potential, Poised to Dominate the Space - Analyst
November 30, 2021 7:44 AM ESTEarlier today, MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin announced that the pivotal Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma (FL) patients who received at least two prior systemic therapies demonstrated a 70.3% objective response rate (ORR) as determined by Independent Review Committee (IRC) assessment in the primary efficacy population (n=91). In addition, 35.2% of patients achieved a complete... More
MEI Pharma (MEIP) Climbs 35% Following Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib
November 30, 2021 7:18 AM ESTMEI Pharma (NASDAQ: MEIP) Climbs 35% Following Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib
... MoreMEI Pharma (MEIP) to Host Webcast on November 30, 2021 at 8:00 a.m. ET Reporting Data from Ongoing Global Phase 2 TIDAL Study of Zandelisib in Patients with Follicular Lymphoma
November 29, 2021 4:00 PM ESTMEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the company will host a live investor and analyst webcast on Tuesday, November 30, 2021 reporting on data from the ongoing global Phase 2 TIDAL study evaluating... More
